Governing biomedical innovation

My colleague Brian Salter and I have a comment piece on the BioNews website today, in which we discuss the move by the UK government to establish a new advisory committee for emerging biomedical science. We pose a number of questions about the remit and scope of the new committee and conclude by suggesting that emerging science is not the only source of governance challenges in the sphere of biomedical innovation – established technologies also create policy problems, a point exemplified by the recent PIP breast implant scandal.

Advertisements